Tokyo Tape
Sign in
← OncoTherapy Science

Annual report

4564.TEDINET S100OBQJ
Period2021-04-01 → 2022-03-31
Filed2022-06-21
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 124
MetricValuePeriodScopeSource row
Revenue¥1.2bn2021-04-01 → 2022-03-31Cons.Net sales
Revenue¥332m2020-04-01 → 2021-03-31Cons.Net sales
Operating income−¥2.1bn2021-04-01 → 2022-03-31Cons.Operating income
Operating income−¥1.6bn2020-04-01 → 2021-03-31Cons.Operating income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income
Ordinary income−¥1.6bn2020-04-01 → 2021-03-31Cons.Ordinary income
Ordinary income−¥2.2bn2019-04-01 → 2020-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥3.0bn2018-04-01 → 2019-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥3.0bn2017-04-01 → 2018-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥2.6bn2021-04-01 → 2022-03-31Cons.Income before income taxes
Profit before tax−¥1.6bn2020-04-01 → 2021-03-31Cons.Income before income taxes
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.6bn2020-04-01 → 2021-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.9bn2018-04-01 → 2019-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.9bn2017-04-01 → 2018-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss
Net income−¥1.6bn2020-04-01 → 2021-03-31Cons.Profit loss
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥3.4bnat 2021-03-31Cons.Assets
Total assets¥5.1bnat 2020-03-31dCons.Total assets (5-year summary)
Total assets¥5.4bnat 2019-03-31dCons.Total assets (5-year summary)
Total assets¥8.0bnat 2018-03-31dCons.Total assets (5-year summary)
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Total liabilities¥291mat 2021-03-31Cons.Liabilities
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥3.1bnat 2021-03-31Cons.Net assets
Net assets / equity¥4.7bnat 2020-03-31dCons.Net assets
Net assets / equity¥4.9bnat 2019-03-31dCons.Net assets (5-year summary)
Net assets / equity¥7.6bnat 2018-03-31dCons.Net assets (5-year summary)
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
Cash and deposits¥2.9bnat 2021-03-31Cons.Cash and deposits
Cash & equivalents¥1.8bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2021-03-31Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2020-03-31dCons.Cash and cash equivalents
Cash & equivalents¥4.9bnat 2019-03-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥6.7bnat 2018-03-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥2.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.8bn2020-04-01 → 2021-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.3bn2019-04-01 → 2020-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥2.4bn2018-04-01 → 2019-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥3.0bn2017-04-01 → 2018-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥468m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥52m2020-04-01 → 2021-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥31m2019-04-01 → 2020-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥74m2018-04-01 → 2019-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥446m2017-04-01 → 2018-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities
Financing cash flow¥2.2bn2019-04-01 → 2020-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥566m2018-04-01 → 2019-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥151m2017-04-01 → 2018-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.862020-04-01 → 2021-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.732019-04-01 → 2020-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-19.92018-04-01 → 2019-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-19.392017-04-01 → 2018-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥9.84at 2022-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥16.96at 2021-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥25.81at 2020-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥30.32at 2019-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥47.44at 2018-03-31dCons.Net assets per share (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio88.8%at 2021-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.5%at 2020-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio85.6%at 2019-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio87.0%at 2018-03-31dCons.Equity to asset ratio (5-year summary)
Employees67at 2022-03-31Cons.Number of employees
Employees66at 2021-03-31Cons.Number of employees
Employees62at 2020-03-31dCons.Number of employees
Employees63at 2019-03-31dCons.Number of employees
Employees56at 2018-03-31dCons.Number of employees
Operating income−¥2.0bn2021-04-01 → 2022-03-31StandaloneOperating income
Operating income−¥1.4bn2020-04-01 → 2021-03-31StandaloneOperating income
Ordinary income−¥2.0bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income−¥1.3bn2020-04-01 → 2021-03-31StandaloneOrdinary income
Ordinary income−¥1.8bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥2.2bn2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥2.7bn2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.4bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Profit before tax−¥1.5bn2020-04-01 → 2021-03-31StandaloneIncome before income taxes
Net income−¥2.4bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income−¥1.5bn2020-04-01 → 2021-03-31StandaloneProfit loss
Net income−¥2.0bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income−¥3.4bn2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Net income−¥2.6bn2017-04-01 → 2018-03-31dStandaloneNet income loss (5-year summary)
Total assets¥2.1bnat 2022-03-31StandaloneAssets
Total assets¥2.9bnat 2021-03-31StandaloneAssets
Total assets¥4.6bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥4.6bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total assets¥7.5bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥418mat 2022-03-31StandaloneLiabilities
Total liabilities¥245mat 2021-03-31StandaloneLiabilities
Net assets / equity¥1.7bnat 2022-03-31StandaloneNet assets
Net assets / equity¥2.6bnat 2021-03-31StandaloneNet assets
Net assets / equity¥4.3bnat 2020-03-31dStandaloneNet assets
Net assets / equity¥4.2bnat 2019-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥7.1bnat 2018-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2022-03-31StandaloneCash and deposits
Cash and deposits¥2.4bnat 2021-03-31StandaloneCash and deposits
EPS (basic)¥-12.942021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-8.772020-04-01 → 2021-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-12.132019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-23.052018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-17.852017-04-01 → 2018-03-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥8.38at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥14.53at 2021-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥23.31at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥25.75at 2019-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥45.89at 2018-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio76.3%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.5%at 2021-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.0%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.2%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.0%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued192,643,700at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued176,332,000at 2021-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued176,332,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued151,557,400at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued147,032,000at 2018-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees36at 2022-03-31StandaloneNumber of employees
Employees35at 2021-03-31StandaloneNumber of employees
Employees32at 2020-03-31dStandaloneNumber of employees
Employees37at 2019-03-31dStandaloneNumber of employees
Employees40at 2018-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 55
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2021-04-01 → 2022-03-31¥952,000
Reconciling Itemsreconcilingdepreciation2021-04-01 → 2022-03-31¥6m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2022-03-31−¥9m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2022-03-31−¥9m
Reconciling Itemsreconcilingsegment assetsat 2022-03-31−¥683m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2022-03-31−¥368m
Cancer Precision Medical Businessreportable segmentcapex2021-04-01 → 2022-03-31¥468m
Cancer Precision Medical Businessreportable segmentemployeesat 2022-03-3131 pure
Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥1.2bn
Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥1.1bn
Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2022-03-31¥8m
Cancer Precision Medical Businessreportable segmentsegment assetsat 2022-03-31¥1.0bn
Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2022-03-31−¥49m
Research And Development Of Pharmaceutical Productsreportable segmentcapex2021-04-01 → 2022-03-31¥2m
Research And Development Of Pharmaceutical Productsreportable segmentdepreciation2021-04-01 → 2022-03-31¥11m
Research And Development Of Pharmaceutical Productsreportable segmentemployeesat 2022-03-3136 pure
Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2022-03-31¥7m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2022-03-31¥7m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2022-03-31¥166,000
Research And Development Of Pharmaceutical Productsreportable segmentsegment assetsat 2022-03-31¥2.3bn
Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2022-03-31−¥1.6bn
—segment totalcapex2021-04-01 → 2022-03-31¥469m
—segment totaldepreciation2021-04-01 → 2022-03-31¥11m
—segment totalrevenue2021-04-01 → 2022-03-31¥1.2bn
—segment totalrevenue external2021-04-01 → 2022-03-31¥1.2bn
—segment totalrevenue intersegment2021-04-01 → 2022-03-31¥9m
—segment totalsegment assetsat 2022-03-31¥3.4bn
—segment totalsegment profit2021-04-01 → 2022-03-31−¥1.7bn
Reconciling Itemsreconcilingcapex2020-04-01 → 2021-03-31¥29m
Reconciling Itemsreconcilingdepreciation2020-04-01 → 2021-03-31¥15m
Reconciling Itemsreconcilingrevenue2020-04-01 → 2021-03-31−¥50m
Reconciling Itemsreconcilingrevenue intersegment2020-04-01 → 2021-03-31−¥50m
Reconciling Itemsreconcilingsegment assetsat 2021-03-31¥6m
Reconciling Itemsreconcilingsegment profit2020-04-01 → 2021-03-31−¥214m
Cancer Precision Medical Businessreportable segmentcapex2020-04-01 → 2021-03-31¥11m
Cancer Precision Medical Businessreportable segmentrevenue2020-04-01 → 2021-03-31¥272m
Cancer Precision Medical Businessreportable segmentrevenue external2020-04-01 → 2021-03-31¥221m
Cancer Precision Medical Businessreportable segmentrevenue intersegment2020-04-01 → 2021-03-31¥50m
Cancer Precision Medical Businessreportable segmentsegment assetsat 2021-03-31¥254m
Cancer Precision Medical Businessreportable segmentsegment profit2020-04-01 → 2021-03-31−¥293m
Research And Development Of Pharmaceutical Productsreportable segmentcapex2020-04-01 → 2021-03-31¥2m
Research And Development Of Pharmaceutical Productsreportable segmentdepreciation2020-04-01 → 2021-03-31¥34m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue2020-04-01 → 2021-03-31¥111m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2020-04-01 → 2021-03-31¥111m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2020-04-01 → 2021-03-31¥55,000
Research And Development Of Pharmaceutical Productsreportable segmentsegment assetsat 2021-03-31¥3.1bn
Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2020-04-01 → 2021-03-31−¥1.1bn
—segment totalcapex2020-04-01 → 2021-03-31¥13m
—segment totaldepreciation2020-04-01 → 2021-03-31¥34m
—segment totalrevenue2020-04-01 → 2021-03-31¥383m
—segment totalrevenue external2020-04-01 → 2021-03-31¥332m
—segment totalrevenue intersegment2020-04-01 → 2021-03-31¥50m
—segment totalsegment assetsat 2021-03-31¥3.4bn
—segment totalsegment profit2020-04-01 → 2021-03-31−¥1.4bn
Research And Development Of Pharmaceutical Productsreportable segmentemployeesat 2022-03-3136 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,183
ItemContextValueUnit
Increase in property plant and equipment and intangible assetsPrior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember10821000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_ReportableSegmentsMember12720000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration_ReconcilingItemsMember29238000JPY
Increase in property plant and equipment and intangible assetsPrior1YearDuration41959000JPY
Revenues from external customersCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember7165000JPY
Revenues from external customersCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember1146498000JPY
Revenues from external customersCurrentYearDuration_ReportableSegmentsMember1153663000JPY
Revenues from external customersCurrentYearDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYearDuration1153663000JPY
Transactions with other segmentsCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember166000JPY
Transactions with other segmentsCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember8333000JPY
Transactions with other segmentsCurrentYearDuration_ReportableSegmentsMember8500000JPY
Transactions with other segmentsCurrentYearDuration_ReconcilingItemsMember-8500000JPY
Transactions with other segmentsCurrentYearDuration－JPY
Net salesCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember7331000JPY
Net salesCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember1154831000JPY
Net salesCurrentYearDuration_ReportableSegmentsMember1162163000JPY
Net salesCurrentYearDuration_ReconcilingItemsMember-8500000JPY
Net salesCurrentYearDuration1153663000JPY
Operating incomeCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-1635896000JPY
Operating incomeCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember-48633000JPY
Operating incomeCurrentYearDuration_ReportableSegmentsMember-1684530000JPY
Operating incomeCurrentYearDuration_ReconcilingItemsMember-368107000JPY
Operating incomeCurrentYearDuration-2052637000JPY
AssetsCurrentYearInstant_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember2346753000JPY
AssetsCurrentYearInstant_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember1021016000JPY
AssetsCurrentYearInstant_ReportableSegmentsMember3367770000JPY
AssetsCurrentYearInstant_ReconcilingItemsMember-682570000JPY
AssetsCurrentYearInstant2685199000JPY
Depreciation segment informationCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember11025000JPY
Depreciation segment informationCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_ReportableSegmentsMember11025000JPY
Depreciation segment informationCurrentYearDuration_ReconcilingItemsMember5515000JPY
Depreciation segment informationCurrentYearDuration16540000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember1680000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember467740000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_ReportableSegmentsMember469420000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_ReconcilingItemsMember952000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration470372000JPY
Impairment loss elPrior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember－JPY
Impairment loss elPrior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember10821000JPY
Impairment loss elPrior1YearDuration_UnallocatedAmountsAndEliminationMember－JPY
Impairment loss elPrior1YearDuration10821000JPY
Impairment loss elCurrentYearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember50183000JPY
Impairment loss elCurrentYearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember467740000JPY
Impairment loss elCurrentYearDuration_UnallocatedAmountsAndEliminationMember29850000JPY
Impairment loss elCurrentYearDuration547773000JPY
Cash and depositsPrior1YearInstant_NonConsolidatedMember2395146000JPY
Cash and depositsCurrentYearInstant_NonConsolidatedMember1161270000JPY
Accounts receivable tradePrior1YearInstant_NonConsolidatedMember110273000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 20 of 20 passed
balance sheet identityconsolidated 2021-03-31pass rounding
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identitynon_consolidated 2021-03-31pass rounding
balance sheet identitynon_consolidated 2022-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2020-03-31pass
statement vs summary · net assetsconsolidated 2021-03-31pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2020-03-31pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2020-04-01/2021-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2020-04-01/2021-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · total assetsconsolidated 2021-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2021-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass